Humana.

PRIOR AUTHORIZATION REQUEST FORM

EOC ID:

Cytokines and CAM Antagonists 56 Phone: 1-800-555-2546 Fax to: 1-877-486-2621

Humana manages the pharmacy drug benefit for your patient. Certain requests for prior authorization require additional information from the prescriber. Please provide the following information and fax this form to the number listed above. **Information left blank or illegible may delay the review process.**

For Medicare Private-Fee-For-Service members, prior authorization is not required for medications covered under Part B. The information below is needed for a Part B versus Part D determination for these members.

Patient name:		Prescriber name:	
Member/subscriber number:		Fax:	Phone:
Patient date of birth:		Office contact:	
Group number:		NPI:	Tax ID:
Address:		Address:	
City, state, ZIP:		City, state, ZIP:	
		Specialty/facility nam	e (if applicable):
Drug name:	Expedi	ted/exigent/urgent	
Directions/SIG:	member has	By checking this box, I certify an expedited/exigent/urgent review is required. The member has a health condition that may seriously jeopardize his/her life or ability to regain maximum function. (Please include explanation of exigency in the space below.)	
Quantity:			
Please attach pertinent medical history of Q1. Please provide diagnosis: *			
Q2. Please provide J-Code, if applie	cable:		
Q3. Please provide ICD Diagnostic	Codes:		
Q3. Please provide ICD Diagnostic Q4. Is the drug being requested one			
		Remicade	
Q4. Is the drug being requested one		☐ Remicade ☐ Renflexis	
Q4. Is the drug being requested one			

Simponi

Skyrizi

Stelara

Simponi Aria

Entyvio

🗌 llumya

Inflectra

Kevzara

☐ Kineret

EOC ID:

Cytokines and CAM Antagonists 56 Phone: 1-800-555-2546 Fax back to: 1-877-486-2621

Patient Name:	Prescriber Name:		
☐ Olumiant	Tremfya		
☐ Orencia	☐ None of the above		
Otezla			
Q5. Please indicate where the drug is being dispensed? *			
Pharmacy dispensed to patient			
Pharmacy shipped to prescriber			
Prescriber dispensed			
Other			
Q6. If other, please specify: *			
Q7. Please indicate if this request is a: *			
New start/ initial request	Continuation/ reauthorization request		
Q8. Does the patient have a clinical response to requeste	d therapy? *		
☐ Yes	□ No		
Q9. Is the drug requested part of a clinical trial?			
Yes	□ No		
Q10. If yes, please provide the registration or identification number for the specific trial for which this drug is being studied (e.g. ClinicalTrials.gov Identifier: NCT12345678): *			
Q11. Does the patient have a negative tuberculin test (TB) prior to initiating therapy? *			
☐ Yes	□ No		
Q12. Is the patient 18 years of age or older? *			
☐ Yes	□ No		
Q13. Does the patient have a diagnosis of Ankylosing Spone	dylitis? *		
☐ Yes	□ No		
Q14. Has the patient had a trial, intolerance or contraindic	cation to any of the following? (Please mark all that apply) *		
A trial at maximum dose for at least 2 – 3 weeks or (NSAIDs)	f one or more non-steroidal anti-inflammatory drugs		
Analgesic agents (acetaminophen or codeine)if NS	SAIDs do not completely control the pain		
Sulfasalazine (if peripheral joint involvement is present)			
At least one of the preferred drugs (e.g. Cosentyx,	Enbrel, or Humira)		

EOC ID:

Cytokines and CAM Antagonists 56 Phone: 1-800-555-2546 Fax back to: 1-877-486-2621

Patient Name:	Prescriber Name:			
□ None of the above				
Q15. Does the patient have a diagnosis of moderate to seve	ere Crohn's Disease? *			
☐ Yes	□ No			
Q16. Has the patient had a trial, intolerance or contraindication to any of the following? (Please mark all that apply) * Budesonide, mesalamine, or corticosteroids (e.g.prednisone or methylprednisolone) Humira				
Non-biologic DMARDs (e.g. azathioprine, methotrexate, mercaptopurine) None of the above				
Q17. Does the patient have a diagnosis of moderate to seve	ere plaque psoriasis of at least a six month duration? *			
☐ Yes	□ No			
Q18. Do any of the following apply to the patient's diagnosis: (Please mark all that apply) *				
Incapacitation due to plaque location (e.g. head ar	nd neck, palms, or genitalia)			
Involvement of at least 10 percent of body surface	area (BSA)			
Psoriasis Area and Severity Index (PASI) score of	12 or greater			
□ None of the above				
Q19. Does the patient have any important active clinical in	nfections? *			
☐ Yes	□ No			
Q20. Has the patient had a minimum three month trial, int mark all that apply) *	colerance or contraindication to any of the following: (Please			
Phototherapy (e.g. Psoralens with UVA light (PUV	A) or UVB with coal tar or dithranol)			
Systemic agent (e.g. immunosuppresives, retinoic	acid derivatives, and/or methotrexate)			
□ None of the above				
Q21. Has the patient had a trial of at least one of the preferred drugs (e.g. Cosentyx, Enbrel, or Humira) and experienced inadequate response or intolerance? *				
☐ Yes	□ No			
Q22. Does the patient have a diagnosis of active psoriatic a	rthritis for at least a six month duration? *			
☐ Yes	□ No			
Q23. Do any of the following apply to the patient's diagno	sis: (Please mark all that apply) *			
greater than or equal to three swollen joints				
greater than or equal to three tender joints				
none of the above				

EOC ID:

Cytokines and CAM Antagonists 56 Phone: 1-800-555-2546 Fax back to: 1-877-486-2621

Patient Name:	Prescriber Name:		
Q24. Has the patient had a trial, intolerance or contraindication to any of the following? (Please mark all that apply) *			
(NSAIDs)	one of more non-steroidal ant-inhammatory drugs		
One or more non-biologic disease modifying anti-rheumatic drugs (DMARDs) (e.g. methotrexate, sulfasalazine, leflunomide, cyclosporine)			
 At least one of the preferred drugs (e.g. Cosentyx, None of the above 	Enbrel, Xeljanz IR or Humira)		
Q25. Does the patient have a diagnosis of moderate to seve	re rheumatoid arthritis? *		
☐ Yes	□ No		
Q26. Has the patient had a trial, intolerance or contraindic	ation to any of the following? (Please mark all that apply) *		
One or more non-biologic DMARDs (e.g. methotrexate, leflunomide, sulfasalazine, hydroxychloroquine) for at least 3 consecutive months			
At least one of the preferred drugs (e.g. Enbrel, Humira, or Xeljanz IR)			
□ None of the above			
Q27. Does the patient have a diagnosis of moderately to sev	verely active ulcerative colitis (UC)? *		
☐ Yes	□ No		
Q28. Has the patient had a trial, intolerance or contraindic	cation to any of the following? (Please mark all that apply) *		
At least one of the preferred drugs (e.g. Humira or	Xeljanz IR)		
Oral mesalamine			
Oral corticosteroids (e.g. prednisone, dexamethas	one, methylprednisolone)		
6-mercaptopurine (6-MTP)			
Has demonstrated corticosteroid dependence			
None of the above			
Q29. Does the patient have a diagnosis of juvenile idiopathic arthritis? *			
	□ No		
Q30. Has the patient had a trial, intolerance or contraindic	cation to any of the following: (Please mark all that apply) *		
Enbrel			
One or more non-steroidal anti-inflammatory (NSA	IDs)		
One or more non-biologic DMARDs (e.g. methotrexate, sulfasalazine)			
□ None of the above			
Q31. Does the patient have any of the following diagnoses:			

EOC ID:

Cytokines and CAM Antagonists 56 Phone: 1-800-555-2546 Fax back to: 1-877-486-2621

Patient Name:	Prescriber Name:	
Cryopyrin Associated Periodic Syndromes (CAPS): Muckle-Wells Syndrome, Familial Cold Autoinflammatory Syndrome, Neonatal-Onset Multisystem Inflammatory Disease / Chronic Infantile Neurological, Cutaneous, Articular Syndrome		
Tumor Necrosis Factor Receptor Associated Periodic Syndrome		
Hyperimmunoglobulin D Syndrome / Mevalonate Kinase Deficiency		
Familial Mediterranean Fever		
□ None of the above		
Q32. Does the patient have a diagnosis of Polyarticular Juve	enile Idiopathic Arthritis (PJIA)?	
☐ Yes	🗌 No	
Q33. Has the patient had a trial, intolerance or contraindic	cation to any of the following: (Please mark all that apply) *	
At least one of the preferred drugs (e.g. Enbrel or l	Humira)	
One or more non-steroidal anti-inflammatory (NSA		
One or more non-biologic DMARDs (e.g. methotre		
\square None of the above		
Q34. Does the patient have a diagnosis of axial spondyloarth inflammation? *	hritis, non-radiographic with objective signs of	
☐ Yes	□ No	
Q35. Has the patient had a trial, intolerance or contraindic	cation to any of the following: (Please mark all that apply) *	
A trial at maximum dose for at least 2-3 weeks of c	one or more non-steroidal anti-inflammatory drugs (NSAIDs)	
Analgesic agents (acetaminophen or codeine) if N	SAIDs do not completely control the pain	
□ None of the above		
Q36. Does the patient have a diagnosis of oral ulcers associ	iated with Behcet's disease? *	
☐ Yes	□ No	
Q37. Has the patient have a trial, contraindication, or intol apply): *	erance to any of the following (Please mark all that	
Triamcinolone oral paste		
 Immunosuppressive agents (e.g. azathioprine, hydroxic) 	droxychloroquine, colchicine)	
□ minumosuppressive agents (e.g. azatiliophine, hydroxychioroquine, colonicine)		
Q38. Additional comments:		

Prescriber signature

EOC ID:

Cytokines and CAM Antagonists 56 Phone: 1-800-555-2546 Fax back to: 1-877-486-2621

Patient Name:

Humana.

Prescriber Name:

I declare under penalty of perjury under the laws of the United States of America that the information provided is true and correct. This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately. 3149ALL0917-B 2020-1-1